Phase I study of camrelizumab in patients with advanced solid tumors

Detalles Bibliográficos
Autores principales: Ma, Yuxiang, Cao, Jiaxin, Zhang, Yang, Liu, Qianwen, Fang, Wenfeng, Yang, Yunpeng, Zhao, Yuanyuan, Yang, Qing, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892498/
https://www.ncbi.nlm.nih.gov/pubmed/36725836
http://dx.doi.org/10.1038/s41392-022-01213-6
_version_ 1784881337098829824
author Ma, Yuxiang
Cao, Jiaxin
Zhang, Yang
Liu, Qianwen
Fang, Wenfeng
Yang, Yunpeng
Zhao, Yuanyuan
Yang, Qing
Zhao, Hongyun
Zhang, Li
author_facet Ma, Yuxiang
Cao, Jiaxin
Zhang, Yang
Liu, Qianwen
Fang, Wenfeng
Yang, Yunpeng
Zhao, Yuanyuan
Yang, Qing
Zhao, Hongyun
Zhang, Li
author_sort Ma, Yuxiang
collection PubMed
description
format Online
Article
Text
id pubmed-9892498
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98924982023-02-03 Phase I study of camrelizumab in patients with advanced solid tumors Ma, Yuxiang Cao, Jiaxin Zhang, Yang Liu, Qianwen Fang, Wenfeng Yang, Yunpeng Zhao, Yuanyuan Yang, Qing Zhao, Hongyun Zhang, Li Signal Transduct Target Ther Letter Nature Publishing Group UK 2023-02-01 /pmc/articles/PMC9892498/ /pubmed/36725836 http://dx.doi.org/10.1038/s41392-022-01213-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter
Ma, Yuxiang
Cao, Jiaxin
Zhang, Yang
Liu, Qianwen
Fang, Wenfeng
Yang, Yunpeng
Zhao, Yuanyuan
Yang, Qing
Zhao, Hongyun
Zhang, Li
Phase I study of camrelizumab in patients with advanced solid tumors
title Phase I study of camrelizumab in patients with advanced solid tumors
title_full Phase I study of camrelizumab in patients with advanced solid tumors
title_fullStr Phase I study of camrelizumab in patients with advanced solid tumors
title_full_unstemmed Phase I study of camrelizumab in patients with advanced solid tumors
title_short Phase I study of camrelizumab in patients with advanced solid tumors
title_sort phase i study of camrelizumab in patients with advanced solid tumors
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892498/
https://www.ncbi.nlm.nih.gov/pubmed/36725836
http://dx.doi.org/10.1038/s41392-022-01213-6
work_keys_str_mv AT mayuxiang phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT caojiaxin phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT zhangyang phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT liuqianwen phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT fangwenfeng phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT yangyunpeng phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT zhaoyuanyuan phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT yangqing phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT zhaohongyun phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors
AT zhangli phaseistudyofcamrelizumabinpatientswithadvancedsolidtumors

Ejemplares similares